Analyst firms · Morgan Stanley · NPCE
Morgan Stanley NPCE price target and rating history
Neuropace Inc. (NPCE) · Health Care
Morgan Stanley rates Neuropace Inc. (NPCE) Equal-Weight with a $6 price target, as of its latest action on Aug 24, 2023. It has published 3 rating actions on NPCE since November 2021, including 1 upgrade and 2 downgrades. Across 4 firms with a NPCE price target in the last 12 months, the median target is $13.50.
- Current rating
- Equal-Weight
- Price target
- $6
- Median target, all firms
- $13.50
- Actions on NPCE
- 3
Morgan Stanley price target on NPCE
Every Morgan Stanley rating on NPCE
- Aug 24, 2023
- Jan 7, 2022
- Nov 11, 2021
How other firms rate NPCE
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wells Fargo | Equal Weight | $9 | Nov 13, 2026 |
| Leerink Partners | Market Perform | $7 | Nov 13, 2026 |
| KeyBanc Capital Markets | Overweight | $18 | Sep 18, 2026 |
| Mizuho | Outperform | $22 | Jul 23, 2026 |
Questions about Morgan Stanley and NPCE
- What is Morgan Stanley's price target for NPCE?
- Morgan Stanley's latest stated price target for Neuropace Inc. (NPCE) is $6, from its action on Aug 24, 2023.
- What is Morgan Stanley's rating on NPCE?
- Morgan Stanley rates NPCE Equal-Weight, a neutral rating, as of Aug 24, 2023.
- When did Morgan Stanley last change its view on NPCE?
- On Aug 24, 2023, Morgan Stanley upgrades to Equal-Weight from Underweight, price target $5 to $6.
- How does Morgan Stanley's NPCE target compare with other analysts?
- Across 4 firms with a NPCE price target in the last 12 months, the median target is $13.50.
More NPCE rating histories
All Morgan Stanley ratingsNPCE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.